EUVIMEDEUVIMED entdecken
Crossref

Adjusting Starting Points for Initial Price Offers: The Example of Ibrutinib

Jason B Gibbons, Charles L Bennett, Kenneth R Carson, Gerard F Anderson

The American Journal of Managed Care · 2024

DOI: 10.37765/ajmc.2024.89531 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The American Journal of Managed Care, 2024. Verfasst von Jason B Gibbons und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Policy and Management, Johns Hopkins University Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD 21205. Email: j…. Hauptthemen laut MEDLINE: Drug Costs, Medicare, Piperidines.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Inflation Reduction Act of 2022 (IRA) allows the Medicare program to negotiate drug prices beginning in 2024. Based on the guidance in the statute, CMS has selected specific data items to use to adjust initial price offers for 10 drugs in the decision-making process. Although much of the data are publicly available, some of these data items will need to be collected directly from drug companies. A 2019 US House of Representatives Committee on Oversight and Accountability investigative report collected a wide range of data from manufacturers of 12 high-revenue drugs that show what is available from the drug companies, including development costs, marketing, pricing, competition, and patent status. This article focuses on the data obtained for ibrutinib, an oral medication for treating hematologic malignancies, which is one of the only drugs reviewed by the committee that also has been selected for Medicare price negotiation. We examine data that can be obtained only from the drug manufacturer that the IRA has explicitly identified as being used to determine the price and suggest potential negotiation strategies for CMS in response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug CostsMedicarePiperidinesAgedHumansUnited StatesEconomic CompetitionDrug IndustryAdenine

Substanzen

ibrutinibAdeninePiperidines

Autor:innen und Institutionen

  • Department of Health Policy and Management, Johns Hopkins University Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD 21205. Email: jgibbo13@jhu.edu.

Zitieren

APA

Gibbons, J. B., Bennett, C. L., Carson, K. R., & Anderson, G. F. (2024). Adjusting Starting Points for Initial Price Offers: The Example of Ibrutinib. The American Journal of Managed Care. https://doi.org/10.37765/ajmc.2024.89531

Vancouver

Gibbons JB, Bennett CL, Carson KR, Anderson GF. Adjusting Starting Points for Initial Price Offers: The Example of Ibrutinib. The American Journal of Managed Care. 2024. doi:10.37765/ajmc.2024.89531

BibTeX
@article{Gibbons2024,
  author = {Gibbons, Jason B and Bennett, Charles L and Carson, Kenneth R and Anderson, Gerard F},
  title = {Adjusting Starting Points for Initial Price Offers: The Example of Ibrutinib},
  journal = {The American Journal of Managed Care},
  year = {2024},
  doi = {10.37765/ajmc.2024.89531}
}
Kostenlos starten →